Results 121 to 130 of about 111,076 (331)

Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort [version 2; referees: 1 approved, 2 approved with reservations]

F1000Research, 2018
Background: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US.  Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for ...
Waqas Amin, Faina Linkov, Douglas P. Landsittel, Jonathan C. Silverstein, Michael J. Becich   +4 more
doaj   +1 more source

SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma [PDF]

, 2018
SYSTEMS-2 is a randomised study of radiotherapy dose escalation for pain control in 112 patients with malignant pleural mesothelioma (MPM). Standard palliative (20Gy/5#) or dose escalated treatment (36Gy/6#) will be delivered using advanced radiotherapy ...
Alexander, L., Ashton, M., Chalmers, A.J., Currie, S., Franks, K., Kelly, C., Laird, B., Macleod, N., Moore, K., O'Rourke, N., Stobo, J., Valentine, R.   +11 more
core   +2 more sources

Erased by law: Kinship, care, and bureaucratic exclusion at the end of life in South Korea

Medical Anthropology Quarterly, EarlyView.
Abstract This article examines how institutional frameworks in South Korea erase nonlegal caregiving relationships within hospice care environments. Drawing on seven months of ethnographic fieldwork, the study delineates how patients are categorized as “unclaimed” despite the presence of long‐term companions or cohabitants who provide intimate end‐of ...
Seok Joo Youn
wiley   +1 more source

Dose de-escalation of intrapleural tissue plasminogen activator therapy for pleural infection. The alteplase dose assessment for Pleural infection Therapy project [PDF]

, 2017
Rationale: Intrapleural therapy with a combination of tissue plasminogen activator (tPA) 10 mg and DNase 5 mg administered twice daily has been shown in randomized and open-label studies to successfully manage over 90% of patients with pleural infection ...
Bintcliffe, Oliver, Blyth, Kevin G., De Fonseka, Duneesha, Edey, Anthony, Lee, Y. C. Gary, Martin, Geoffrey, Maskell, Nick, Piccolo, Francesco, Popowicz, Natalia, Smith, Nicola A., Wong, Donny   +10 more
core   +1 more source

A Case of Malignant Pericardial Mesothelioma With Constrictive Pericarditis Physiology Misdiagnosed as Pericardial Metastatic Cancer [PDF]

, 2011
Man‐Jong Lee, Dae Hyeok Kim, Jun Kwan, Keum Soo Park, Sung‐Hee Shin, Seoung Il Woo, Sang‐Don Park, Won Seop Lee   +7 more
openalex   +1 more source

Cancer heterogeneity explored through immune cell deconvolution of the tumor microenvironment

Quantitative Biology, Volume 14, Issue 3, September 2026.
Abstract Cancer is a highly heterogeneous disease, characterized by significant variability across multiple dimensions. This diversity has been extensively studied from various perspectives. In this study, we aim to examine cancer heterogeneity through the lens of immune cell composition within the tumor microenvironment.
Limin Jiang, Chung‐I Li, Rui Xin, Jijun Tang, Yan Guo   +4 more
wiley   +1 more source

Malignant mesothelioma in rare sites: two case reports

Frontiers in Oncology
Mesothelioma is a rare tumor originating from mesothelial cells in the pleura or other sites. Malignant pleural mesothelioma (MPM) is the most common aggressive type of mesothelioma (accounting for 81%) and carries a poor prognosis (median OS: 1 year ...
Qiguang Du, Jialu Guo, Zi Zhu, Yutong Zhang, He Cui, Zhongkai Xu, Rang Yang, Wenlong Liang   +7 more
doaj   +1 more source

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, Volume 158, Issue 12, Page 3091-3100, 15 June 2026.
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source

Asbestos Lessons: The Consequences of Asbestos Litigation [PDF]

, 2007
not ...
Carrington, Paul D.
core   +1 more source

Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine [PDF]

, 2020
National Cancer Institute
openalex   +1 more source